Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1314 • 2013 ACR/ARHP Annual Meeting
Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis
Maria Di Cicco¹, Stephen Kelly¹, Frances Humby², Nora Ng¹, Sabrina Dadoun³, Rebecca Hands², Vidalba Rocher², Alessandra Nerviani¹, Michele Bombardieri² and Costantino Pitzalis⁴, ¹William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³APHP, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom
Background/Purpose: Predicting response to anti-TNF alpha inhibitors (TNFi) in rheumatoid arthritis (RA) patients is challenging. Therefore there is a high need for identification of biomarkers…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 2401 • 2013 ACR/ARHP Annual Meeting
Disease Activity (DAS-28CRP) In Rheumatoid Arthritis Correlates With Synovial Expression Of Tumor-Associated and IL-6-Dependent Genes
Bernard Lauwerys¹, Julie Ducreux², Adrien Nzeusseu Toukap¹, Valérie Badot³, Frédéric A. Houssiau² and Patrick Durez¹, ¹Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: The molecular mechanisms that regulate disease activity in rheumatoid arthritis (RA) are unknown. Using high-throughput transcriptomic data sets generated in knee synovial biopsies from…
Abstract Number: 2127 • 2013 ACR/ARHP Annual Meeting
Recurrences Of Hallux Valgus Deformity After Implant Surgery For Greater Toe In Rheumatoid Arthritis
Yuichi Mochida¹, Katsushi Ishii¹, Yuji Yamada¹, Naoto Mitsugi² and Tomoyuki Saito³, ¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ²Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan, ³Orthopaedic Surgery, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: In advanced cases of rheumatoid arthritis (RA), Swanson implant have been widely usedfor hallux valgus deformity. Although the results for this surgery were acceptable,…
Abstract Number: 1295 • 2013 ACR/ARHP Annual Meeting
Mechanisms For Fostamatinib-Induced Blood Pressure Elevation
Matthew Skinner¹, Karen Philp¹, David Lengel², Lucy Coverley¹, Eva Lamm Bergstroem³, Philip Glaves¹, Helen Musgrove¹, Helen Prior¹, Martin Braddock⁴, Russell Huby¹, Jon O Curwen¹, Paul Duffy¹ and Alex Harmer¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²AstraZeneca R&D Waltham, Waltham, MA, ³AstraZeneca R&D Mölndal, Mölndal, Sweden, ⁴AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom
Background/Purpose: Fostamatinib is a kinase inhibitor with activity at spleen tyrosine kinase. In clinical studies in patients with rheumatoid arthritis, fostamatinib treatment was associated with…
Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Peter Dawes¹, Aleksandar Dimic², Mark C. Genovese³, Désiréé van der Heijde⁴, Martin Jenkins⁵, Chris O'Brien⁶, Barry Oemar⁷, Jiri Vencovsky⁸ and Michael Weinblatt⁹, ¹Department of Rheumatology, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, ²Rheumatology Institute, Niška Banja, Serbia, ³Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁶AstraZeneca R&D Wilmington, Wilmington, DE, ⁷AstraZeneca R&D Boston, Boston, MA, ⁸Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…
Abstract Number: 2382 • 2013 ACR/ARHP Annual Meeting
B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Anne-Priscille Trouvin¹, Serge Jacquot², Sébastien Grigioni³, Hélène Boulard¹, Ingrid Dutot², Olivier Vittecoq⁴, Xavier Le Loët⁵, Olivier Boyer⁶ and Vincent Goëb⁷, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²INSERM U905, University of Rouen, Rouen, France, ³Pain and Nutrition, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Immunology, INSERM U905, University of Rouen, Rouen, France, ⁷Rheumatology, Amiens University Hospital, Amiens, France
Background/Purpose: Rituximab is a safe and effective treatment in rheumatoid arthritis (RA), however the current treatment regimen requires to wait for a clinical relapse before…
Abstract Number: 1978 • 2013 ACR/ARHP Annual Meeting
The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare
Homaira Rahimi¹, Vaseem Chengazi², Gregory Dieudonne², Edward M. Schwarz³ and Christopher T. Ritchlin⁴, ¹Pediatrics, University of Rochester, Rochester, NY, ²Radiology, University of Rochester, Rochester, NY, ³Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Episodic flare occurs in rheumatoid arthritis (RA) but the mechanisms of this process are not well understood. Our prior reports on MRI analysis of…
Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Mark Genovese¹, Désiréé van der Heijde², Edward Keystone³, Alberto Spindler⁴, Claude-Laurent Benhamou⁵, Arthur Kavanaugh⁶, Edward Fudman⁷, Kathy Lampl⁸, Chris O'Brien⁸, Emma Duffield⁹, Jeffrey Poiley¹⁰ and Michael Weinblatt¹¹, ¹Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³University of Toronto, Toronto, ON, Canada, ⁴Centro Medico Privado de Reumatologia, Tucuman, Argentina, ⁵Centre Hospitalier Régional d'Orléans, Orleans, France, ⁶University of California San Diego, San Diego, CA, ⁷Austin Rheumatology Research PA, Austin, TX, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁰Arthritis Associates, Orlando, FL, ¹¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
MC Genovese¹, Joel M. Kremer², Ronald F. van Vollenhoven³, Rieke Alten⁴, Juan José Scali⁵, Ariella Kelman⁶, Lucy Rowell⁷ and Laura Pitts⁷, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany Medical College, Albany, NY, ³Karolinska Institute, Stockholm, Sweden, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵Durand University Hospital, Buenos Aires, Argentina, ⁶Genentech, South San Francisco, CA, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
Abstract Number: 2354 • 2013 ACR/ARHP Annual Meeting
Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Dong-Jin Park¹, Kyung-Eun Lee¹, Ji-Hyoun Kang², Jeong-Won Lee², Tae-Jong Kim³, Yong-Wook Park¹ and Shin-Seok Lee⁴, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Chonnam National University Medical School, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: We investigated the compliance of Korean patients using anti-tumor necrosis factor (TNF) agents to treat rheumatoid arthritis (RA) and anklyosing spondylitis (AS), and identified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].